Effects of Piracetam as an Adjuvant Therapy on Attention Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

AUTHORS

Kaveh Alavi 1 , Elham Shirazi 1 , * , Maryam Akbari 1 , Zahra Shahrivar 2 , Fatemeh-Sadat Noori 3 , Soosan Shirazi 4

1 Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran

2 Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran

3 Spiritual Health Research Center, Iran University of Medical Sciences, Tehran, Iran

4 Graduate Student of Clinical Psychology, Women Research Center, Alzahra University, Tehran, Iran

How to Cite: Alavi K , Shirazi E, Akbari M, Shahrivar Z , Noori F, et al. Effects of Piracetam as an Adjuvant Therapy on Attention Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Iran J Psychiatry Behav Sci.2021 In Press(In Press): e59421. doi: 10.5812/ijpbs.59421.

ARTICLE INFORMATION

Iranian Journal of Psychiatry and Behavioral Sciences: In Press (In Press); e59421
Published Online: June 05, 2021
Article Type: Research Article
Received: October 28, 2019
Revised: September 07, 2020
Accepted: April 03, 2021
Primary Published scheduled for 15 (1)
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background: Stimulants are highly effective in controlling symptoms of ADHD, but 30% of affected individuals do not respond to them or cannot tolerate their side effects, thus alternative treatment approaches need to be considered.

Objectives: To evaluate the effect and safety of piracetam as an adjuvant therapy plus methylphenidate (MPH) in children with Attention Deficit Hyperactivity Disorder (ADHD).

Methods: Thirty six children with ADHD (6-16 year old), who were admitted in three academic outpatient child psychiatric clinics in second half of 2015, were randomly assigned to the “methylphenidate plus piracetam group and the “methylphenidate plus placebo” group, in a double-blind, placebo-controlled study, for 6 weeks. The “Conner’s Parents’ Rating Scale-Revised (CPRS-R), Children Symptom Inventory-4 (CSI-4) Clinical Global Impression-Improvement scale (CGI-I), and Children’ Global Assessment Scale (CGAS) were completed at baseline and at the ends of the 3rd and the 6th week, and the New York state Psychiatric Institute side effect forms were completed weekly, as outcome measures.

Results: The level of improvement in CPRS-R, CSI-4, and CGI-I scales were significantly higher in the “methylphenidate plus piracetam” group compared to the “methylphenidate plus placebo” group. Side effects were not remarkable in any group.

Conclusions: Piracetam as a short-term adjuvant treatment to methylphenidate can have considerable therapeutic effect and safety profile in children with ADHD and deserves further exploration to assess its potentialities in ADHD treatment.

Fulltext

© 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: